Löfling, Lukas http://orcid.org/0000-0002-2731-8532
Bahmanyar, Shahram
Kieler, Helle
Lambe, Mats
Wagenius, Gunnar
Funding for this research was provided by:
Cancerfonden (15–0804 and 18–0689)
Karolinska Institute
Article History
Received: 20 October 2020
Accepted: 2 March 2021
First Online: 22 March 2021
Declarations
:
: Lukas Löfling, Shahram Bahmanyar, and Helle Kieler are employees at the Centre for Pharmacoepidemiology at Karolinska Institutet, which receives funding from several entities (pharmaceutical companies, regulatory agencies, and contract research organizations). Mats Lambe declares stock ownership in Pfizer and Astra Zeneca. Gunnar Wagenius has no conflict of interest to declare. The funding bodies had no role in the data collection and analysis and were not involved in the interpretation of results, writing, revision, or approval of the manuscript.
: This study was approved by the Regional Ethical Review Boards in Uppsala and Stockholm (record number: 2012/1162–31/4, 2016/1137–32, 2017/445–32, 2017/2026–32).
: This study only includes register data, and the research was done without patient involvement.
: This study only includes register data, and the research was done without patient involvement.